维普中文期刊产品整合服务
19篇 您的检索式:作者名="Lodise Jr"
    题名 作者 年代 出处 被引量
1Pharmaeodynamic profiling of piperacillin in the prsence of tazobaetam in patients through the use of population phanmcokinetic modds and monte carlo simulation 显示文摘Lodise Jr TP Lomaestm B Rodvold KA 2004Antimicvob Agents Chemother2004,48,12:1
2Burden of methicillin-resistant Staphylococcus aureus: focus on clinical and economic outcomes显示文摘Thomas P Lodise Jr Peggy SM 2007Pharmacotherapy2007,27,7:1
3Piperacillin-tazobactam for Pseudomonas aeruginosa infection:clinical implications of an extended-infusion dosing strategy显示文摘Lodise TP Jr Lomaestro B Drusano GL 2007Clin Infect Dis2007,44,3:1
4Impact of empirical - therapy selection on outcomes of intravenous drug users with infective endocarditis caused by methicillin -susceptible staphylococcus anreus 显示文摘Thomas P Lodise JR Peggy S 2007Antimicrobial Agents and Chemotherapy2007,51,:1
5Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended- infusiondosing strateg显示文摘Lodise T P Jr Lomaestro B Drusano G L 2007Clin Infect Dis2007,44,3:1
6Piperacillintazobactam for Pseudomonas aeruginosa infection- Clinical im-plications of an extended-infusion dosing strategy 显示文摘Lodise TP Jr Lomaestro B Drusano GL 2007Clin In-fect Dis2007,44,:1
7Predictors of 30-day mortality among patients with Pseudomonas aerugino- sa bloodstream infections: impact of delayed appropriate anti- biotic selection显示文摘LODISE T P JR PATEL N KWA A 2007Antimicrob Agents Chemother2007,51,10:1
8Piperacillin-tazo- bactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy显示文摘Lodise TP Jr Lomaestro B Drusano GL 2007Clin Infect Dis2007,44,3:1
9Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections:impact of delayed appropriate antibiotic selection 显示文摘Lodise TP Jr Patel N Kwa A 2007Antimicrob Agents Chemother2007,51,10:1
10Piperacillin-tazobactam for Pseudomonas aeruginosa infection:clinical implications of an extended-infusion dosing strategy显示文摘Lodise TP Jr Lomaestro B Drusano GL 2007Clin Infect Dis2007,44,3:1
11Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended- infusion dosing strategy 显示文摘Lodise TP Jr Lomaestro B Drusano GL 2007Clin Infect Dis2007,44,3:1
12Piperacillin- tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy显示文摘Lodise TP Jr Lomaestro B Drusano GL 2007Clin Infect Dis2007,44,3:1
13Telavancin pen- etration into human epithelial lining fluid determined by popu- lation pharmacokinetic modeling and Monte Carlo simulation 显示文摘Lodise TP Jr Gotfried M Barriere S 2008Antimicrob Agents Chemother2008,52,7:1
14Piperacillin tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy显示文摘Lodise TP Jr Lomaestro B Drusano GL 2007Clin Infect Dis2007,44,3:1
15Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended infusion dosing strategy显示文摘Jr Lodise TP Lomaestro B Drusano GL 2007Clin Infect Dis2007,44,3:1
16Piperacillin-tazobactam for Pseudomonas aeruginosa infection:clinical implications of an extended-infusion dosing strategy显示文摘Lodise TP Jr Lomaestro B Drusano GL 2007Clin Infect Dis2007,44,3:1
17Probability of target attainment for ceftobiprole as derived from a population pharmacokinetie analysis of 150 subjects显示文摘Lodise T P Jr Pypstra R Kahn J B 2007Antimicrob Agents Chemother2007,51,7:1
18Piperacillin-tazobac- tam for Pseudomonas aeruginosa infection : clinical implications of an extended-infusion dosing strategy显示文摘Lodise TP Jr Lomaestro B Drusano GL 2007Clin Infect Dis2007,44,3:1
19Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections:impact of delayed appropriate antibiotic selection显示文摘Lodise TP Jr Patel N Kwa A 2007Antimicrob Agents Chemother2007,51,:1
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费